Drug Profile
Research programme: heart failure therapeutics - Orion
Latest Information Update: 22 Sep 2009
Price :
$50
*
At a glance
- Originator Orion
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 22 Sep 2009 Discontinued - Preclinical for Heart failure in Finland (unspecified route)
- 08 Nov 2006 Preclinical trials in Heart failure in Finland (unspecified route)